2026-04-29T20:38:53Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/52432024-05-15T10:40:08Zcom_10259_4725com_10259_5086com_10259_2604col_10259_4726
González López, Tomás José
637
500
Sánchez González, Blanca
55e39874-d12c-4ccc-a9f2-2030d1391630
500
Jarque, Isidro
9146c85e-30d1-4ab4-9ceb-e96d1103e6c0
500
Bernat, Silvia
2ce94b47-9e36-4628-8a40-d415cf7eb6ba
500
Fernández Fuertes, Fernando
c9099636-c3da-4300-bf07-7c31f6405585
500
Caparrós, Isabel
5031ad94-b501-4b5b-8d57-97fa54d859e5
500
Soto, Inmaculada
ba3805c7-270a-4fbf-ae84-b2014e44fd63
500
Fernández Rodríguez, Angeles
f570f6f7-23a2-438a-af1c-0b6c6f15cfb3
500
Bolaños, Estefanía
176ce65e-010e-485a-ac38-045a8331b716
500
Pérez Rus, Gloria
a92bb0e5-dbf7-46d7-9fe5-3bc6dd6aa6d0
500
Pascual, Cristina
d9479e99-4d3e-4df1-9d3c-6901a4fafa52
500
Hernández Rivas, José Angel
2eab20f8-2d7e-4c53-9a5f-0e96a3fba055
500
López Ansoar, Elsa
19eaa0ed-09b4-4c46-84e0-54f3e0e6355c
500
Gómez Nuñez, Marta
73984215-ea4e-40c3-a5a5-212f85262b3e
500
Martínez Robles, Violeta
367e98db-823e-46d2-9e03-a6a48a08a0b6
500
Olivera, Pavel
ba554cb0-03e7-4366-84d3-a0dc4e1c0c12
500
Yera Cobo, Maria
39410fa9-eaa8-401e-9b1f-a089a0326756
500
Peñarrubia, María Jesús
8aabf628-f6b3-4566-896d-177e8ffea00b
500
Fernández Miñano, Carmen
4522745c-825a-4480-87de-94800881c3a5
500
Cabo, Erik
e4cdd0e6-fcad-4620-b75c-ba9651d4f142
500
Martínez Badas, María Paz
cadffe34-50e9-46bc-8b5c-eee5e06dc79e
500
Perdomo Hernández, Germán M.
433
500
0000-0003-0348-4082
García Frade, Luis Javier
e2ef7d74-51da-4924-aa3b-3c5b1abd5e03
500
2020-03-13T11:04:12Z
2020-03-13T11:04:12Z
2020-03
0902-4441
http://hdl.handle.net/10259/5243
10.1111/ejh.13370
1600-0609
Background
Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our ≥65‐year‐old population.
Methods
A total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated.
Results
Median age of our cohort was 76 (interquartile range, IQR, 70‐81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8‐21) days. Median time on response was 320 (IQR, 147‐526) days. Sixty‐three adverse events (AEs), mainly grade 1‐2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self‐limited pulmonary embolisms in secondary ITP were the only thrombotic events observed.
Conclusion
Eltrombopag showed efficacy and safety in ITP patients aged ≥65 years with primary and secondary ITP. However, efficacy results in LPD‐ITP were poor. A relatively high number of deaths were observed.
application/pdf
eng
John Wiley & Sons
European Journal of Haematology. 2020, V. 104, n. 3, p. 259-270
https://doi.org/10.1111/ejh.13370
Elderly
Eltrombopag
Immune thrombocytopenia
Primary
Secondary
Aparato circulatorio-Enfermedades
Cardiovascular system-Diseases
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
info:eu-repo/semantics/openAccess
European Journal of Haematology
104
3
259
270
TEXT
Gonzalez-ejh_2020.pdf.txt
Gonzalez-ejh_2020.pdf.txt
Extracted text
text/plain
56434
https://riubu.ubu.es/bitstream/10259/5243/4/Gonzalez-ejh_2020.pdf.txt
59ed43c538c31223dd9820d076e484f6
MD5
4
THUMBNAIL
Gonzalez-ejh_2020.pdf.jpg
Gonzalez-ejh_2020.pdf.jpg
IM Thumbnail
image/jpeg
4609
https://riubu.ubu.es/bitstream/10259/5243/3/Gonzalez-ejh_2020.pdf.jpg
85a7e529f483701009def4082cdedbc0
MD5
3
LICENSE
license.txt
license.txt
text/plain; charset=utf-8
999
https://riubu.ubu.es/bitstream/10259/5243/2/license.txt
b295bcbce42e2caabeb0c623d3860c06
MD5
2
ORIGINAL
Gonzalez-ejh_2020.pdf
Gonzalez-ejh_2020.pdf
application/pdf
1168416
https://riubu.ubu.es/bitstream/10259/5243/1/Gonzalez-ejh_2020.pdf
00cd80f4ac116b700aedf8b2fa4d5252
MD5
1
10259/5243
oai:riubu.ubu.es:10259/5243
2024-05-15 12:40:08.623
Repositorio Institucional de la Universidad de Burgos
bubrep@ubu.es
RWwgYXV0b3IgY29tbyDDum5pY28gdGl0dWxhciBkZSBsb3MgZGVyZWNob3MgZGUgcHJvcGllZGFkIGludGVsZWN0dWFsIGRlIGxhIG9icmEsIG8gZGlzcG9uaWVuZG8gZGUgbG9zIGRlYmlkb3MgcGVybWlzb3MgZGUgbG9zIG90cm9zIHRpdHVsYXJlcywgc2kgbG9zIGh1YmllcmEsIHkgZW4gdmlydHVkIGRlIGxvcyBkZXJlY2hvcyBxdWUgbGUgY29uZmllcmUgbGEgbGVnaXNsYWNpw7NuIHZpZ2VudGUgc29icmUgcHJvcGllZGFkIGludGVsZWN0dWFsIHkgZGVyZWNob3MgZGUgYXV0b3IsIA0KQVVUT1JJWkEgYSBsYSBVbml2ZXJzaWRhZCBkZSBCdXJnb3MgYSBkaWZ1bmRpciwgZGUgbWFuZXJhIGdyYXR1aXRhLCBlbCBjb250ZW5pZG8gZGUgbG9zIGFyY2hpdm9zIGRpZ2l0YWxlcyBxdWUgY29ycmVzcG9uZGVuIGFsIGRvY3VtZW50byBkZXNjcml0byBhbnRlcmlvcm1lbnRlLCBjb24gY2Fyw6FjdGVyIG5vIGV4Y2x1c2l2byB5IGRlIG1hbmVyYSBww7pibGljYSBlbiBhY2Nlc28gYWJpZXJ0byBhIHRyYXbDqXMgZGUgSW50ZXJuZXQsIHBhcmEgbG8gcXVlIGxhIEJpYmxpb3RlY2EgcHJvY2VkZXLDoSBhIGFyY2hpdmFybG9zIGVuIGVsIFJlcG9zaXRvcmlvIEluc3RpdHVjaW9uYWwuIEFzaW1pc21vIGF1dG9yaXphIGEgbGEgVW5pdmVyc2lkYWQgZGUgQnVyZ29zIGEgcmVhbGl6YXIgbGFzIHRyYW5zZm9ybWFjaW9uZXMgbmVjZXNhcmlhcyBkZSBmb3JtYXRvLCBubyBkZSBjb250ZW5pZG8sIHBhcmEgZ2FyYW50aXphciBsYSBwcmVzZXJ2YWNpw7NuIHkgZWwgYWNjZXNvIGVuIGVsIGZ1dHVyby4NCg0KRWwgYXV0b3IgZGlzcG9uZSwgZW4gdG9kbyBjYXNvLCBkZWwgZGVyZWNobyBhIHJldm9jYXIgZXN0YSBhdXRvcml6YWNpw7NuLg0KDQpMYSBjZXNpw7NuIGRlIGRlcmVjaG9zIGRlIGVzdGEgb2JyYSBzZSBlbmN1ZW50cmEgc3VqZXRhIGEgbGEgbGVnaXNsYWNpw7NuIHZpZ2VudGUgc29icmUgcHJvcGllZGFkIGludGVsZWN0dWFsIHkgZGVyZWNob3MgZGUgYXV0b3Iu